Recurrent Chronic Lymphocytic Leukemia (DBCOND0029141)

Identifiers

Synonyms

Chronic lymphocytic leukaemia recurrent / Chronic, recurrent Lymphocytic leukaemia / Recurrent Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia Recurrent / Chronic, recurrent Lymphocytic Leukemia / Chronic lymphoid leukemia in relapse (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Ofatumumab	An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.	B-lymphocyte antigen CD20target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03853616	MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)	Tisagenlecleucel	treatment	1 / 2	recruiting
NCT05705570	A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting
NCT04892277	CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT06343376	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT01638533	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction	Romidepsin	treatment	1	active_not_recruiting
NCT02948283	Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia	Metformin Ritonavir	treatment	1	completed
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT03579888	CD19-Specific T Cells Post AlloSCT	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT04205409	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Nivolumab	treatment	2	active_not_recruiting
NCT02160015	Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery	Ibrutinib Lenalidomide Rituximab	treatment	1	active_not_recruiting
NCT04169737	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Obinutuzumab Tyrosine Venetoclax	treatment	2	recruiting
NCT01886859	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Ibrutinib Lenalidomide	treatment	1	completed
NCT02225275	Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Lenalidomide Obinutuzumab	treatment	2	terminated
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT03246906	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Cyclophosphamide Cyclosporine Mycophenolate mofetil Sirolimus	treatment	2	active_not_recruiting
NCT00764517	Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma	Cladribine Rituximab Vorinostat	treatment	2	completed
NCT00060424	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT04941716	Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Tyrosine Venetoclax	treatment	2	recruiting
NCT02662296	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant	Ibrutinib Idelalisib	treatment	2	withdrawn
NCT03807063	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Rimiducid Rivogenlecleucel	treatment	1	withdrawn
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT01231412	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil Sirolimus	treatment	3	completed
NCT04781855	Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation	Ibrutinib Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT04029038	Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma	Cyclophosphamide Fludarabine	treatment	1 / 2	withdrawn
NCT00005803	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Beta-D-Glucose Carmustine Cyclophosphamide Cyclosporine Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil	treatment	1 / 2	completed
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT02869633	Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Ibrutinib	treatment	2	completed
NCT01527045	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Atorvastatin Cyclosporine Fludarabine Mycophenolate mofetil	prevention	2	completed
NCT02756897	Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia	Ibrutinib Venetoclax	treatment	2	active_not_recruiting
NCT03045328	Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL	Ibrutinib Venetoclax	treatment	2	completed
NCT05418088	Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT01822509	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	Ipilimumab Nivolumab	treatment	1	completed
NCT02530515	Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia	No drug interventions	treatment	2	completed
NCT01251575	Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil Sirolimus	treatment	2	completed
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT03010358	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Entospletinib Obinutuzumab	treatment	1 / 2	completed
NCT01008462	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Beta-D-Glucose Carmustine Cyclophosphamide Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT02153580	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia	Bendamustine Beta-D-Glucose Cyclophosphamide Etoposide Fludarabine	treatment	1	active_not_recruiting
NCT02332980	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	Ibrutinib Idelalisib Pembrolizumab	treatment	2	completed
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT02007044	Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Ibrutinib Rituximab	treatment	2	active_not_recruiting
NCT04230304	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	Daratumumab Ibrutinib	treatment	2	active_not_recruiting
NCT03961672	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Duvelisib	treatment	2	active_not_recruiting
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT01003769	Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia	Isosorbide Lenalidomide	treatment	1 / 2	terminated
NCT02420912	Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation	Ibrutinib Nivolumab	treatment	2	completed
NCT02928510	Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma	Idelalisib	Not Available	Not Available	terminated
NCT02593123	Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis	Filgrastim Mycophenolate mofetil Sargramostim	treatment	2	completed
NCT02614508	Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Buparlisib Ibrutinib Ofatumumab	treatment	1	terminated